Literature DB >> 11576940

Impaired secretion of parathyroid hormone is coherent to diabetic hemodialyzed patients.

M Inaba1, S Okuno, K Nagasue, T Otoshi, Y Kurioka, K Maekawa, Y Kumeda, Y Imanishi, E Ishimura, T Ohta, H Morii, M Kim, Y Nishizawa.   

Abstract

Diabetic bone disease is characterized by low bone turnover resulting from impaired secretion of parathyroid hormone (PTH). However, it was suggested that the difference in duration of hemodialysis (HD) therapy and age of patients between HD patients with and without diabetes mellitus (DM) may be responsible for a significant reduction in serum intact PTH (iPTH) level in HD patients with DM. The present study showed that although such major factors affecting PTH secretion as age, sex, HD duration, and serum calcium, phosphate, and magnesium levels did not differ significantly between HD patients with and without DM, serum iPTH levels were still significantly lower in HD patients with than without DM. Among biochemical markers for bone metabolism, serum levels of intact osteocalcin (iOC) and deoxypyridinoline (DPD) were significantly lower in HD patients with than without DM, whereas serum bone-specific alkaline phosphatase, pyridinoline, and beta-crosslaps did not differ significantly between the two groups of patients. In summary, our findings indicate that PTH secretion may be significantly impaired in HD patients with DM compared with those without DM, and serum iOC and DPD are bone markers sensitive enough to detect low bone turnover in HD patients with DM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576940     DOI: 10.1053/ajkd.2001.27423

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  5 in total

Review 1.  Bone mineral density in patients on maintenance dialysis.

Authors:  Csaba Ambrus; Adrienn Marton; Zsofia Klara Nemeth; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-12-29       Impact factor: 2.370

2.  Predictors of acquired perforating dermatosis in uremic patients on hemodialysis: a case-control study.

Authors:  Cheng-Hao Weng; Ching-Chih Hu; Shir-Hwa Ueng; Chun-Chen Yu; Chung-Yee Hui; Ja-Liang Lin; Chih-Wei Yang; Cheng-Chieh Hung; Ching-Wei Hsu; Tzung-Hai Yen
Journal:  ScientificWorldJournal       Date:  2012-12-11

3.  Pulse versus daily oral Alfacalcidol treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized controlled trial.

Authors:  Osama Sawalmeh; Shaheed Moala; Zakaria Hamdan; Huda Masri; Khubaib Ayoub; Emad Khazneh; Mujahed Shraim
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-01-15

Review 4.  Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.

Authors:  Jianzhen Ye; Guangrui Deng; Feng Gao
Journal:  Drug Des Devel Ther       Date:  2018-04-19       Impact factor: 4.162

5.  Lower bone mineral density and higher bone resorption marker levels in premenopausal women with type 1 diabetes in Japan.

Authors:  Fumi Yoshioka; Shinsuke Nirengi; Takashi Murata; Yaeko Kawaguchi; Tomokazu Watanabe; Kunio Saeki; Muneto Yoshioka; Naoki Sakane
Journal:  J Diabetes Investig       Date:  2021-04-03       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.